Treat DVT with Low Molecular Weight Heparin

Cheryl Nadeau, Jerry Varrone

Research output: Contribution to journalArticlepeer-review


Each year, deep vein thrombosis (DVT) affects two million Americans, and pulmonary embolism (PE) affects 600,000. Traditional treatment requires hospitalization to receive continuous intravenous unfractionated heparin (UFH), which has substantial pharmacokinetic limitations. Low molecular weight heparins have overcome many of these limitations, resulting in a predictable anticoagulant response without the need for laboratory monitoring or dosage adjustment.

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalNurse Practitioner
Issue number10
StatePublished - Oct 2003

ASJC Scopus subject areas

  • General Nursing


Dive into the research topics of 'Treat DVT with Low Molecular Weight Heparin'. Together they form a unique fingerprint.

Cite this